|
|
|
|
The intravitreal market is growing fast, with nearly 70 pipeline programs in development and 7% volume growth projected through 2029. But packaging missteps around contamination, endotoxins, and dosing precision can stall your program or harm patients — get the guidance to make smarter packaging decisions earlier.
|
|
|
|
|
Evolving ophthalmic regulations are reshaping how developers approach compliance, product quality, and patient safety. Learn how USP <789> limits, the revised EU GMP Annex 1, and a comprehensive Contamination Control Strategy come together to keep you compliant.
|
|
|
|
|
Comprehensive endotoxin control strategies are essential to patient safety and regulatory compliance. Discover how to strengthen your approach to meet the evolving demands of injectable and advanced pharmaceutical products.
|
|
|
|
|
Intravitreal drug therapies carry unique risks that regulators are scrutinizing more closely than ever. Get expert clarity on EU GMP Annex 1, contamination control strategy requirements, extractables and leachables testing, and container closure integrity standards.
|
|
|
|
|
Driven by rising demand and new clinical trials, the intravitreal therapy market is expanding steadily. Meeting demand while staying compliant requires ophthalmic drug developers to track regulatory updates, adopt new technologies, and maintain rigorous contamination control.
|
|
|
|
|
|
|
|
|
Meet West at PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Palm Springs, California from October 6-7. Team Members will be at Booth 315 to answer questions on our components, pre-fillable syringe systems, services, and devices. To schedule a meeting, please email meetwest@westpharma.com.
|
|
|
